The earnings call reflected a mixed performance for Quanterix with significant strategic advancements such as the Akoya acquisition and expansion in market reach. However, these were offset by notable declines in revenue, instrument placements, and challenges in the academic and pharma sales sectors. The company is actively working towards cost optimization and future growth, but current financials show significant short-term challenges.

Company Guidance -

Q3 2025

During the Quanterix Corporation Q2 2025 earnings call, the company provided guidance emphasizing strategic actions to achieve long-term growth despite current market challenges. The company reported $24.5 million in revenue, a 29% decline year-over-year, due to temporary funding pauses in the academic and pharmaceutical sectors. They highlighted the completion of the Akoya acquisition, which is expected to yield $85 million in synergy savings by 2026, with 75% already realized. Quanterix aims for double-digit revenue growth and margin improvement, projecting $130-$135 million in revenue for 2025, with GAAP gross margins between 49%-53% and non-GAAP gross margins between 45%-49%. The company is focused on becoming cash flow positive by 2026, leveraging its expanded addressable market now valued at $5 billion, and growing its presence in neurology, immunology, and oncology. They are also advancing the launch of Simoa One, which promises to significantly increase their installed base and expand their market reach.

Akoya Acquisition and Integration

Completed the transformative Akoya acquisition, which is expected to generate $85 million in synergy savings and cost reductions. 75% of these expense reductions have already been implemented on a run rate basis.

Expansion in Addressable Market

With the acquisition of Akoya, Quanterix now serves a $5 billion total market across neurology, immunology, and oncology.

Simoa One Platform Launch

The Simoa One platform is set to launch by the end of 2025, expanding the addressable installed base by 20x to over 20,000 systems globally.

Alzheimer's Diagnostic Franchise Development

Expanded partnerships, international regulatory footprint, doubled test volumes, tripled revenues, and on track for a Medicare pricing recommendation this year.

Increased Consumables Revenue

Consumables revenue was approximately $100 million, demonstrating resiliency in the current macro environment.

Cash and Cost Management

Adjusted cash usage during the quarter was $2.6 million, an improvement of 49% from the previous year, driven by improved working capital and cost reductions.

Quanterix (QTRX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

QTRX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.48 / -	-0.219	―	―	―
Aug 07, 2025	2025 (Q2)	-0.42 / -0.77	-0.25	-208.00% (-0.52)
May 12, 2025	2025 (Q1)	-0.43 / -0.53	-0.26	-103.85% (-0.27)
Mar 17, 2025	2024 (Q4)	-0.26 / -0.30	-0.33	9.09% (+0.03)
Nov 12, 2024	2024 (Q3)	-0.24 / -0.22	-0.21	-4.29% (>-0.01)
Aug 08, 2024	2024 (Q2)	-0.27 / -0.25	-0.16	-56.25% (-0.09)
May 07, 2024	2024 (Q1)	-0.31 / -0.26	-0.16	-62.50% (-0.10)
Feb 29, 2024	2023 (Q4)	-0.31 / -0.33	-0.5	34.00% (+0.17)
Nov 06, 2023	2023 (Q3)	-0.37 / -0.21	-0.95	77.89% (+0.74)
Aug 07, 2023	2023 (Q2)	-0.38 / -0.16	-0.67	76.12% (+0.51)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

QTRX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$5.51	$4.75	-13.79%
May 12, 2025	$5.73	$4.64	-19.02%
Mar 17, 2025	$7.28	$7.15	-1.79%
Nov 12, 2024	$15.17	$12.40	-18.26%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Quanterix Corporation (QTRX) report earnings?

Quanterix Corporation (QTRX) is schdueled to report earning on Nov 05, 2025, After Close (Confirmed).

What is Quanterix Corporation (QTRX) earnings time?

Quanterix Corporation (QTRX) earnings time is at Nov 05, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is QTRX EPS forecast?

QTRX EPS forecast for the fiscal quarter 2025 (Q3) is -0.48.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing